Telura Tablet (Lamivudine (300mg) + Tenofovir disoproxil fumarate (300mg) + Efavirenz (600mg))

Telura Tablet is a combination of three antiviral medicines such as Lamivudine (300mg), Tenofovir disoproxil fumarate (300mg) and Efavirenz (600mg). It is prescribed to treat HIV (human immunodeficiency virus) infection and manage AIDS. It works by preventing viruses from multiplying and boosting immunity to fight against the infection. Thereby reducing the amount of virus in the body. It should be taken in dose and duration as advice by the doctor. Don't take more than the recommended dose.

HIV

Telura Tablet is a strong anti-HIV medicine that may show certain adverse while manageable impact on the body during the treatment. As these effects resolve on their own without any special medical attention. However, if you ever experience serious or unusual side effects contact your healthcare professional immediately.
Some common side effects include:
● Diarrhea
● Insomnia (difficulty sleeping)
● Nausea
● Depression
● Headache
● Weakness
● Rash
● Pain
● Fever
● Decreased white blood cell count (neutrophils)
● Peripheral neuropathy (tingling and numbness of feet and hand)
● Back pain
● Abdominal pain
● Anxiety
● Vomiting
● Joint pain
● Pneumonia
● Dyspepsia
● Indigestion
● Muscle pain
● Lipodystrophy (skin thickening or pits at the injection site)
● Cough
● Impaired concentration
● Abnormal dreams
● Dizziness

The dosage and duration of the Telura Tablet are decided by the doctor based on the severity of the infection and other health factors. Take this tablet on an empty stomach for better results. Before starting this medicine, please inform your doctor about your medical history. If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.

● Goicoechea, M., & Best, B. (2007). Efavirenz/emtricitabine/tenofovir disoproxil fumarate fixed-dose combination: first-line therapy for all?. Expert Opinion on Pharmacotherapy, 8(3), 371-382.
● Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., ... & Cheng, A. K. (2006). Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. New England Journal of Medicine, 354(3), 251-260.
● Avihingsanon, A., Gatechompol, S., Sapsirisavat, V., Thiansanguankul, W., Sophonphan, J., Thammajaruk, N., ... & Ruxrungtham, K. (2017). Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults. International Journal of Infectious Diseases, 61, 89-96.
● SANKARAIAH, J., SHARMA, N., & NAIM, M. J. (2022). Formulation And Development Of Fixed-Dose Combination Of Bi-Layer Tablets Of Efavirenz, Lamivudine And Tenofovir Disoproxil Fumarate Tablets 600 Mg/300 Mg/300 Mg. Int J App Pharm, 14(1), 185-197.
● Frampton, J. E., & Croom, K. F. (2006). Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs, 66(11), 1501-1512.
● Dravid, A., Betha, T. P., Sharma, A. K., Gawali, R., Mahajan, U., Kulkarni, M., ... & Rathod, N. (2020). Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India. HIV medicine, 21(9), 578-587.